(Q37799373)

23 August 2017

title

Molecular mechanisms and treatment options for muscle wasting diseases (English)

1 reference

23 August 2017

Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases (English)

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

31 July 2024

1

Markus A. Rüegg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20936944

31 July 2024

2

David J. Glass

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20936944

31 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20936944

31 July 2024

publication date

1 January 2011

1 reference

full work available at URL

23 August 2017

http://arjournals.annualreviews.org/doi/abs/10.1146/annurev-pharmtox-010510-100537

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20936944

https://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-010510-100537

31 July 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Annual Review of Pharmacology and Toxicology

31 July 2024

published in

1 reference

23 August 2017

volume

51

1 reference

23 August 2017

page(s)

373-395

1 reference

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients

31 July 2024

3

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

31 July 2024

The muscular dystrophies

4

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome.

31 July 2024

5

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan

31 July 2024

6

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies

31 July 2024

7

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding.

31 July 2024

8

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies

31 July 2024

9

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Calpains in muscle wasting.

31 July 2024

10

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration.

31 July 2024

12

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mammalian animal models for Duchenne muscular dystrophy

31 July 2024

13

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells

31 July 2024

14

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

31 July 2024

16

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.

31 July 2024

17

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy

31 July 2024

18

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

31 July 2024

19

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

31 July 2024

20

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Current status of gene therapy for muscle diseases

31 July 2024

21

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

AAV-directed muscular dystrophy gene therapy

31 July 2024

22

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model

31 July 2024

23

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype

31 July 2024

24

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery

31 July 2024

25

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications

31 July 2024

26

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein

31 July 2024

27

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping

31 July 2024

28

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

31 July 2024

29

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology

31 July 2024

30

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs

31 July 2024

31

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Local dystrophin restoration with antisense oligonucleotide PRO051

31 July 2024

32

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

31 July 2024

33

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression

31 July 2024

34

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Reverse protein arrays as novel approach for protein quantification in muscular dystrophies

31 July 2024

35

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations

31 July 2024

36

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human

31 July 2024

37

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Execution of nonsense-mediated mRNA decay: what defines a substrate?

31 July 2024

38

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice

31 July 2024

39

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

31 July 2024

40

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle

31 July 2024

41

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations

31 July 2024

42

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

PTC124 targets genetic disorders caused by nonsense mutations

31 July 2024

43

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression

31 July 2024

44

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

31 July 2024

45

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia

31 July 2024

46

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A signaling role for dystrophin: inhibiting skeletal muscle atrophy pathways

31 July 2024

47

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Signaling pathways perturbing muscle mass

31 July 2024

48

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo

31 July 2024

49

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.

31 July 2024

50

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

American Journal of Physiology

31 July 2024

51

259

E89

DeVol DL

1990

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Insulin-like growth factor immunoreactivity increases in muscle after acute eccentric contractions

31 July 2024

52

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture

31 July 2024

53

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice

31 July 2024

54

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle

31 July 2024

55

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy

31 July 2024

56

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

FoxO3 controls autophagy in skeletal muscle in vivo

31 July 2024

57

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice

31 July 2024

58

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Burn injury impairs insulin-stimulated Akt/PKB activation in skeletal muscle

31 July 2024

59

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4.

31 July 2024

60

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth.

31 July 2024

61

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

31 July 2024

62

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

31 July 2024

63

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy

31 July 2024

64

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

31 July 2024

65

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Drosophila S6 kinase: a regulator of cell size

31 July 2024

66

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Regulation of eIF-4E BP1 phosphorylation by mTOR.

31 July 2024

67

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

mTOR-mediated regulation of translation factors by amino acids

31 July 2024

68

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

31 July 2024

69

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism

31 July 2024

70

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

31 July 2024

71

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

31 July 2024

72

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification

31 July 2024

73

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.

31 July 2024

74

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

31 July 2024

75

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

31 July 2024

76

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

31 July 2024

77

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The nuts and bolts of AGC protein kinases

31 July 2024

78

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 July 2024

79

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor

31 July 2024

80

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function

31 July 2024

81

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

31 July 2024

82

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

GSK-3beta negatively regulates skeletal myotube hypertrophy

31 July 2024

83

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

31 July 2024

84

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Glycogen synthase kinase 3 suppresses myogenic differentiation through negative regulation of NFATc3.

31 July 2024

85

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway

31 July 2024

86

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Identification of ubiquitin ligases required for skeletal muscle atrophy

31 July 2024

87

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

31 July 2024

88

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes

31 July 2024

89

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection

31 July 2024

90

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mechanical ventilation induces alterations of the ubiquitin-proteasome pathway in the diaphragm

31 July 2024

91

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The RING finger domain: a recent example of a sequence-structure family

31 July 2024

92

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

31 July 2024

93

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain

31 July 2024

94

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Does this have a familiar RING?

31 July 2024

95

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The tripartite motif family identifies cell compartments

31 July 2024

96

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1

31 July 2024

97

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Transient association of titin and myosin with microtubules in nascent myofibrils directed by the MURF2 RING-finger protein

31 July 2024

98

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle

31 July 2024

99

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation

31 July 2024

100

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The SCF ubiquitin ligase: an extended look

31 July 2024

101

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase

31 July 2024

102

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

31 July 2024

103

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins

31 July 2024

104

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

31 July 2024

105

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy

31 July 2024

106

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B

31 July 2024

107

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Effects of dexamethasone on protein degradation and protease gene expression in rat L8 myotube cultures

31 July 2024

108

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes.

31 July 2024

109

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors

31 July 2024

110

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.

31 July 2024

111

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase

31 July 2024

112

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control

31 July 2024

113

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member

31 July 2024

114

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle

31 July 2024

115

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle

31 July 2024

116

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Double muscling in cattle due to mutations in the myostatin gene

31 July 2024

117

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways

31 July 2024

118

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myostatin inhibits myoblast differentiation by down-regulating MyoD expression.

31 July 2024

119

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.

31 July 2024

120

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo

31 July 2024

121

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1.

31 July 2024

122

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer

31 July 2024

123

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis

31 July 2024

124

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size

31 July 2024

125

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

AN ELECTRON MICROSCOPE STUDY OF DENERVATION ATROPHY IN RED AND WHITE SKELETAL MUSCLE FIBERS

31 July 2024

126

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1

31 July 2024

127

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription

31 July 2024

128

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy

31 July 2024

129

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth

31 July 2024

130

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Mechanisms of cancer cachexia

31 July 2024

131

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice

31 July 2024

132

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Exercise induces myonuclear ubiquitination and apoptosis in dystrophin-deficient muscle of mice

31 July 2024

133

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Physical training in old men

31 July 2024

134

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

American Journal of Physiology

31 July 2024

135

277

E118

Yarasheski KE

1999

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Smad2 and 3 transcription factors control muscle mass in adulthood.

31 July 2024

136

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice

31 July 2024

137

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage

31 July 2024

138

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration

31 July 2024

139

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy.

31 July 2024

140

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?

31 July 2024

141

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene

31 July 2024

142

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle

31 July 2024

143

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy.

31 July 2024

144

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle

31 July 2024

145

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion

31 July 2024

146

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Functional improvement of dystrophic muscle by myostatin blockade.

31 July 2024

147

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice

31 July 2024

148

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice

31 July 2024

149

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality

31 July 2024

150

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs

31 July 2024

151

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

31 July 2024

152

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100537

31 July 2024

Identifiers

1 reference

23 August 2017

1 reference